| Tclin | Receptor activity-modifying protein 1 |
Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for calcitonin-gene-related peptide (CGRP) together with CALCRL.
The protein encoded by this gene is a member of the RAMP family of single-transmembrane-domain proteins, called receptor (calcitonin) activity modifying proteins (RAMPs). RAMPs are type I transmembrane proteins with an extracellular N terminus and a cytoplasmic C terminus. RAMPs are required to transport calcitonin-receptor-like receptor (CRLR) to the plasma membrane. CRLR, a receptor with seven transmembrane domains, can function as either a calcitonin-gene-related peptide (CGRP) receptor or an adrenomedullin receptor, depending on which members of the RAMP family are expressed. In the presence of this (RAMP1) protein, CRLR functions as a CGRP receptor. The RAMP1 protein is involved in the terminal glycosylation, maturation, and presentation of the CGRP receptor to the cell surface. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Apr 2015]
The protein encoded by this gene is a member of the RAMP family of single-transmembrane-domain proteins, called receptor (calcitonin) activity modifying proteins (RAMPs). RAMPs are type I transmembrane proteins with an extracellular N terminus and a cytoplasmic C terminus. RAMPs are required to transport calcitonin-receptor-like receptor (CRLR) to the plasma membrane. CRLR, a receptor with seven transmembrane domains, can function as either a calcitonin-gene-related peptide (CGRP) receptor or an adrenomedullin receptor, depending on which members of the RAMP family are expressed. In the presence of this (RAMP1) protein, CRLR functions as a CGRP receptor. The RAMP1 protein is involved in the terminal glycosylation, maturation, and presentation of the CGRP receptor to the cell surface. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Apr 2015]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Liver Cirrhosis, Experimental | 769 | 0.0 | 0.0 |
| Disease | Target Count |
|---|---|
| Type 1 Diabetes Mellitus Treatment Adjunct | 4 |
| Type 2 Diabetes Mellitus Treatment Adjunct | 7 |
| Disease | Target Count | P-value |
|---|---|---|
| lung adenocarcinoma | 2716 | 8.7e-08 |
| ovarian cancer | 8520 | 3.8e-07 |
| malignant mesothelioma | 3232 | 4.5e-06 |
| atypical teratoid / rhabdoid tumor | 5112 | 1.4e-05 |
| intraductal papillary-mucinous adenoma (IPMA) | 2955 | 5.1e-04 |
| medulloblastoma, large-cell | 6241 | 6.1e-04 |
| interstitial cystitis | 2312 | 2.4e-03 |
| group 3 medulloblastoma | 4104 | 2.7e-03 |
| breast carcinoma | 1638 | 5.4e-03 |
| intraductal papillary-mucinous carcinoma (IPMC) | 2989 | 6.9e-03 |
| active ulcerative colitis | 764 | 8.2e-03 |
| primitive neuroectodermal tumor | 3035 | 9.0e-03 |
| osteosarcoma | 7950 | 1.6e-02 |
| intraductal papillary-mucinous neoplasm (IPMN) | 3291 | 3.1e-02 |
| Disease | log2 FC | p |
|---|---|---|
| active ulcerative colitis | 1.897 | 8.2e-03 |
| atypical teratoid / rhabdoid tumor | -2.600 | 1.4e-05 |
| breast carcinoma | 1.700 | 5.4e-03 |
| group 3 medulloblastoma | -1.400 | 2.7e-03 |
| interstitial cystitis | 1.600 | 2.4e-03 |
| intraductal papillary-mucinous adenoma (... | -2.400 | 5.1e-04 |
| intraductal papillary-mucinous carcinoma... | -1.900 | 6.9e-03 |
| intraductal papillary-mucinous neoplasm ... | -1.600 | 3.1e-02 |
| lung adenocarcinoma | 2.200 | 8.7e-08 |
| malignant mesothelioma | -1.100 | 4.5e-06 |
| medulloblastoma, large-cell | -1.600 | 6.1e-04 |
| osteosarcoma | 1.041 | 1.6e-02 |
| ovarian cancer | -1.300 | 3.8e-07 |
| primitive neuroectodermal tumor | -1.500 | 9.0e-03 |
